vs

Side-by-side financial comparison of Roper Technologies (ROP) and Steris (STE). Click either name above to swap in a different company.

Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.5B, roughly 1.4× Steris). Roper Technologies runs the higher net margin — 15.8% vs 12.9%, a 2.9% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs 9.2%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $199.5M). Over the past eight quarters, Steris's revenue compounded faster (15.8% CAGR vs 10.5%).

Steris plc is an American-Irish-based medical equipment company specializing in sterilization and surgical products for the US healthcare system. Steris is operationally headquartered in Mentor, Ohio, and has been legally registered in Dublin, Ireland, for tax purposes since 2018. Previously the company was registered in the United Kingdom from 2014 to 2018.

ROP vs STE — Head-to-Head

Bigger by revenue
ROP
ROP
1.4× larger
ROP
$2.1B
$1.5B
STE
Growing faster (revenue YoY)
ROP
ROP
+2.1% gap
ROP
11.3%
9.2%
STE
Higher net margin
ROP
ROP
2.9% more per $
ROP
15.8%
12.9%
STE
More free cash flow
ROP
ROP
$307.5M more FCF
ROP
$507.0M
$199.5M
STE
Faster 2-yr revenue CAGR
STE
STE
Annualised
STE
15.8%
10.5%
ROP

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
ROP
ROP
STE
STE
Revenue
$2.1B
$1.5B
Net Profit
$331.0M
$192.9M
Gross Margin
69.4%
43.8%
Operating Margin
27.2%
18.3%
Net Margin
15.8%
12.9%
Revenue YoY
11.3%
9.2%
Net Profit YoY
53.7%
11.2%
EPS (diluted)
$4.87
$1.96

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ROP
ROP
STE
STE
Q1 26
$2.1B
Q4 25
$2.1B
$1.5B
Q3 25
$2.0B
$1.5B
Q2 25
$1.9B
$1.4B
Q1 25
$1.9B
$1.5B
Q4 24
$1.9B
$1.4B
Q3 24
$1.8B
$1.3B
Q2 24
$1.7B
$1.3B
Net Profit
ROP
ROP
STE
STE
Q1 26
$331.0M
Q4 25
$428.4M
$192.9M
Q3 25
$398.5M
$191.9M
Q2 25
$378.3M
$177.4M
Q1 25
$331.1M
$145.7M
Q4 24
$462.3M
$173.5M
Q3 24
$367.9M
$150.0M
Q2 24
$337.1M
$145.4M
Gross Margin
ROP
ROP
STE
STE
Q1 26
69.4%
Q4 25
69.5%
43.8%
Q3 25
69.5%
44.2%
Q2 25
69.2%
45.1%
Q1 25
68.7%
43.3%
Q4 24
68.3%
44.5%
Q3 24
69.2%
43.6%
Q2 24
69.5%
44.7%
Operating Margin
ROP
ROP
STE
STE
Q1 26
27.2%
Q4 25
28.6%
18.3%
Q3 25
28.4%
18.2%
Q2 25
28.2%
17.7%
Q1 25
27.9%
14.6%
Q4 24
28.0%
17.9%
Q3 24
28.1%
16.5%
Q2 24
28.8%
14.5%
Net Margin
ROP
ROP
STE
STE
Q1 26
15.8%
Q4 25
20.8%
12.9%
Q3 25
19.8%
13.1%
Q2 25
19.5%
12.8%
Q1 25
17.6%
9.8%
Q4 24
24.6%
12.7%
Q3 24
20.8%
11.3%
Q2 24
19.6%
11.4%
EPS (diluted)
ROP
ROP
STE
STE
Q1 26
$4.87
Q4 25
$3.97
$1.96
Q3 25
$3.68
$1.94
Q2 25
$3.49
$1.79
Q1 25
$3.06
$1.48
Q4 24
$4.29
$1.75
Q3 24
$3.40
$1.51
Q2 24
$3.12
$1.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ROP
ROP
STE
STE
Cash + ST InvestmentsLiquidity on hand
$382.9M
$423.7M
Total DebtLower is stronger
$9.7B
$1.9B
Stockholders' EquityBook value
$18.8B
$7.2B
Total Assets
$34.6B
$10.6B
Debt / EquityLower = less leverage
0.52×
0.27×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ROP
ROP
STE
STE
Q1 26
$382.9M
Q4 25
$297.4M
$423.7M
Q3 25
$320.0M
$319.2M
Q2 25
$242.4M
$279.7M
Q1 25
$372.8M
$171.7M
Q4 24
$188.2M
$155.2M
Q3 24
$269.6M
$172.2M
Q2 24
$251.5M
$198.3M
Total Debt
ROP
ROP
STE
STE
Q1 26
$9.7B
Q4 25
$9.3B
$1.9B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$1.9B
Q4 24
$7.6B
$2.0B
Q3 24
$2.2B
Q2 24
$2.2B
Stockholders' Equity
ROP
ROP
STE
STE
Q1 26
$18.8B
Q4 25
$19.9B
$7.2B
Q3 25
$20.0B
$7.0B
Q2 25
$19.6B
$7.0B
Q1 25
$19.2B
$6.6B
Q4 24
$18.9B
$6.4B
Q3 24
$18.5B
$6.6B
Q2 24
$18.1B
$6.4B
Total Assets
ROP
ROP
STE
STE
Q1 26
$34.6B
Q4 25
$34.6B
$10.6B
Q3 25
$34.6B
$10.4B
Q2 25
$33.2B
$10.4B
Q1 25
$31.4B
$10.1B
Q4 24
$31.3B
$10.0B
Q3 24
$31.6B
$10.2B
Q2 24
$29.8B
$10.1B
Debt / Equity
ROP
ROP
STE
STE
Q1 26
0.52×
Q4 25
0.47×
0.27×
Q3 25
0.27×
Q2 25
0.27×
Q1 25
0.29×
Q4 24
0.40×
0.32×
Q3 24
0.33×
Q2 24
0.35×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ROP
ROP
STE
STE
Operating Cash FlowLast quarter
$298.2M
Free Cash FlowOCF − Capex
$507.0M
$199.5M
FCF MarginFCF / Revenue
24.2%
13.3%
Capex IntensityCapex / Revenue
0.5%
6.6%
Cash ConversionOCF / Net Profit
1.55×
TTM Free Cash FlowTrailing 4 quarters
$917.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ROP
ROP
STE
STE
Q1 26
Q4 25
$738.0M
$298.2M
Q3 25
$869.5M
$287.8M
Q2 25
$404.1M
$420.0M
Q1 25
$528.7M
$260.8M
Q4 24
$722.2M
$332.8M
Q3 24
$755.4M
$250.7M
Q2 24
$384.1M
$303.7M
Free Cash Flow
ROP
ROP
STE
STE
Q1 26
$507.0M
Q4 25
$199.5M
Q3 25
$201.3M
Q2 25
$326.4M
Q1 25
$189.9M
Q4 24
$243.6M
Q3 24
$148.8M
Q2 24
$195.7M
FCF Margin
ROP
ROP
STE
STE
Q1 26
24.2%
Q4 25
13.3%
Q3 25
13.8%
Q2 25
23.5%
Q1 25
12.8%
Q4 24
17.8%
Q3 24
11.2%
Q2 24
15.3%
Capex Intensity
ROP
ROP
STE
STE
Q1 26
0.5%
Q4 25
6.6%
Q3 25
5.9%
Q2 25
6.7%
Q1 25
4.8%
Q4 24
6.5%
Q3 24
7.7%
Q2 24
8.4%
Cash Conversion
ROP
ROP
STE
STE
Q1 26
Q4 25
1.72×
1.55×
Q3 25
2.18×
1.50×
Q2 25
1.07×
2.37×
Q1 25
1.60×
1.79×
Q4 24
1.56×
1.92×
Q3 24
2.05×
1.67×
Q2 24
1.14×
2.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ROP
ROP

Segment breakdown not available.

STE
STE

Servicerevenues$404.7M27%
Consumablerevenues$387.1M26%
Applied Sterilization Technologies$286.6M19%
Capitalequipmentrevenues$272.1M18%
Life Science$145.8M10%

Related Comparisons